

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Approximately half of clinical investigators and one quarter of practicing oncologists would recommend systemic treatment with chemotherapy and bevacizumab in addition to bisphosphonates for an otherwise healthy 60-year-old asymptomatic postmenopausal woman with metastatic breast cancer who previously received dose-dense AC → paclitaxel for a 1.8-cm triple-negative infiltrating ductal carcinoma (IDC) with 2 positive nodes.  
a. True  
b. False
2. Approximately 95% of clinical investigators and practicing oncologists would choose to primarily observe and not administer systemic therapy for the 60-year-old asymptomatic patient described in question 1.  
a. True  
b. False
3. Both clinical investigators and practicing oncologists would prefer to treat an otherwise healthy 75-year-old postmenopausal patient presenting with symptomatic metastatic breast cancer who previously received dose-dense AC → paclitaxel for a 1.8-cm ER/PR/HER2-negative IDC and 2 positive nodes with \_\_\_\_\_.  
a. Chemotherapy alone  
b. Chemotherapy with bevacizumab  
c. No treatment — observation alone
4. A majority of clinical investigators but not of practicing oncologists would prefer to administer bevacizumab combined with chemotherapy to an otherwise healthy 60-year-old symptomatic postmenopausal patient presenting with metastatic breast cancer who received dose-dense AC → paclitaxel for a 1.8-cm ER/PR/HER2-negative IDC with 2 positive nodes.  
a. True  
b. False